Nexviazyme Approved in Canada as Next-gen ERT for Late-onset Pompe

Nexviazyme Approved in Canada as Next-gen ERT for Late-onset Pompe

312113

Nexviazyme Approved in Canada as Next-gen ERT for Late-onset Pompe

Nexviazyme (avalglucosidase alfa), a next-generation enzyme replacement therapy, has been approved by Health Canada for people with late-onset Pompe disease ages 6 months and older. “The Health Canada approval of Nexviazyme is an important milestone for Canadian Pompe patients and may represent a new standard of care,” Mark Tarnopolsky, MD, PhD, director of the neuromuscular and neurometabolic clinic at McMaster University Medical Center, in Ontario, said in a press release. The therapy will now be…

You must be logged in to read/download the full post.